BLM and BRCA1-BARD1 coordinate complementary mechanisms of joint DNA molecule resolution

Kaima Tsukada,Samuel E. Jones,Julius Bannister,Mary-Anne Durin,Iolanda Vendrell,Matthew Fawkes,Roman Fischer,Benedikt M. Kessler,J. Ross Chapman,Andrew N. Blackford

DOI: https://doi.org/10.1016/j.molcel.2023.12.040

IF: 16

2024-01-26

Molecular Cell

Abstract:Summary The Bloom syndrome helicase BLM interacts with topoisomerase IIIα (TOP3A), RMI1, and RMI2 to form the BTR complex, which dissolves double Holliday junctions and DNA replication intermediates to promote sister chromatid disjunction before cell division. In its absence, structure-specific nucleases like the SMX complex (comprising SLX1-SLX4, MUS81-EME1, and XPF-ERCC1) can cleave joint DNA molecules instead, but cells deficient in both BTR and SMX are not viable. Here, we identify a negative genetic interaction between BLM loss and deficiency in the BRCA1-BARD1 tumor suppressor complex. We show that this is due to a previously overlooked role for BARD1 in recruiting SLX4 to resolve DNA intermediates left unprocessed by BLM in the preceding interphase. Consequently, cells with defective BLM and BRCA1-BARD1 accumulate catastrophic levels of chromosome breakage and micronucleation, leading to cell death. Thus, we reveal mechanistic insights into SLX4 recruitment to DNA lesions, with potential clinical implications for treating BRCA1-deficient tumors.

cell biology,biochemistry & molecular biology